Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

By Peter A. Calabresi, E. Radue, D. Goodin, D. Jeffery, K. Rammohan, A. Reder, T. Vollmer, M. Agius, L. Kappos, T. Stites and 4 more. Lancet Neurology, 2014

745 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/42f1eb7877d85806b1be40b4a308f81eff007678